Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolonged antibiotics to prevent permanent Pseudomonas infection in bronchiectasis
ISRCTN21853061Phase 3Recruiting
- Sponsor
- University of Dundee
- Start
- Mar 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of ciprofloxacin in bronchiectasis and Pseudomonas aeruginosa airway infection (2 arms), sponsored by University of Dundee. Primary endpoint: Frequency of pulmonary exacerbations. Started Mar 2026; status: recruiting.
02
Drugs
ciprofloxacin
03
Conditions
bronchiectasisPseudomonas aeruginosa airway infection
Beyond the preview
Go deeper on ISRCTN21853061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN21853061.